Pharmacology Quiz: Elimination And Clearance
20 questions · exam conditions
0:00
Elimination And ClearanceQuestion 1 of 20

A patient begins therapy with a new drug administered by continuous IV infusion. The drug's elimination half-life is known to be 24 hours. Due to a suboptimal initial response, the physician decides to double the infusion rate after 12 hours of therapy. How will this change in infusion rate affect the time required to reach the final steady-state concentration?

The time to reach steady state will be halved.
The time to reach steady state will be doubled.
The time to reach steady state will not change.
The time to reach steady state will be reset and start from the moment the rate was changed.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Elimination And Clearance

Practice Elimination And Clearance in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Elimination And Clearance, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient begins therapy with a new drug administered by continuous IV infusion. The drug's elimination half-life is known to be 24 hours. Due to a suboptimal initial response, the physician decides to double the infusion rate after 12 hours of therapy. How will this change in infusion rate affect the time required to reach the final steady-state concentration?

  1. The time to reach steady state will be halved.
  2. The time to reach steady state will be doubled.
  3. The time to reach steady state will not change. (correct answer)
  4. The time to reach steady state will be reset and start from the moment the rate was changed.
Explanation: A fundamental principle of pharmacokinetics is that the time to reach steady state is determined solely by the drug's elimination half-life, requiring approximately 4 to 5 half-lives. The rate of infusion determines the value of the steady-state concentration (Css) but not the time it takes to get there. Although the target Css is changed midway, the time to reach the new steady state is still dictated by the original half-life. The approach to the new steady state will begin from the concentration achieved after 12 hours, but the total time from the start of therapy to the final steady state will still be approximately 4-5 half-lives (96-120 hours).
  • A) & B): Incorrect. Infusion rate does not alter the time constant (half-life) that governs the approach to steady state.
  • D): This is a plausible misconception. While the clock for reaching the new specific concentration target starts from the point of change, the underlying kinetic process continues from the initial start time. The overall time from initiation of therapy to final equilibrium remains a function of t₁/₂.

Question 2

A patient in the intensive care unit has overdosed on a toxic substance. The clinical team is considering hemodialysis to enhance its elimination. Which of the following properties of the substance would make it least likely to be effectively removed by hemodialysis?

  1. High water solubility
  2. Molecular weight of 300 Daltons
  3. Volume of distribution of 400 L (correct answer)
  4. Plasma protein binding of 10%
Explanation: Hemodialysis removes substances from the blood. For it to be effective, a significant fraction of the drug in the body must be present in the plasma. A very large volume of distribution (Vd), such as 400 L (much larger than total body water), indicates that the drug is extensively distributed into tissues and is not in the plasma. Therefore, dialysis would only be able to clear the small amount of drug circulating in the blood, making it an ineffective method of removal for the total body burden.
  • A): High water solubility is a favorable property for dialysis, as it allows the drug to readily dissolve in the dialysate.
  • B): A low to moderate molecular weight (typically < 500 Daltons) is favorable, allowing the molecule to pass through the pores of the dialysis membrane.
  • D): Low plasma protein binding is favorable, as only the unbound drug can be removed by dialysis.

Question 3

A patient stabilized on warfarin (a low-extraction drug with a narrow therapeutic index, metabolized by CYP2C9) is started on fluconazole, a potent inhibitor of CYP2C9. Which of the following pharmacokinetic changes is the primary driver of the clinically significant interaction?

  1. A decrease in the hepatic extraction ratio of warfarin
  2. A reduction in the intrinsic clearance of warfarin (correct answer)
  3. An increase in hepatic blood flow
  4. Displacement of warfarin from albumin binding sites
Explanation: Warfarin is a low-extraction drug, meaning its clearance is capacity-limited and described by the equation CL ≈ fu × CL_int. Fluconazole inhibits CYP2C9, the enzyme responsible for warfarin's metabolism. This directly reduces the intrinsic clearance (CL_int), which is a measure of the metabolic capacity of the liver. This reduction in CL_int is the primary mechanism that leads to decreased overall clearance, increased half-life, and accumulation of warfarin to potentially toxic levels.
  • A): While a decrease in intrinsic clearance will lead to a decrease in the extraction ratio, the fundamental cause is the change in CL_int, not the other way around.
  • C): Hepatic blood flow does not significantly influence the clearance of low-extraction drugs.
  • D): While some drugs can displace warfarin from albumin, increasing the unbound fraction (fu), this effect is often transient and less significant than the profound and sustained effect of metabolic inhibition on intrinsic clearance.

Question 4

A new drug is being studied. The hepatic blood flow (Qh) in the subject is 90 L/hr. The drug concentration in the blood entering the liver (portal vein) is 12 µg/mL, and the concentration in the blood exiting the liver (hepatic vein) is 3 µg/mL. What is the hepatic clearance of this drug?

  1. 0.75 L/hr
  2. 22.5 L/hr
  3. 67.5 L/hr (correct answer)
  4. 108 L/hr
Explanation: This is a two-step problem. First, calculate the hepatic extraction ratio (E) using the concentrations entering (Ca) and exiting (Cv) the liver: E = (Ca - Cv) / Ca. Here, E = (12 µg/mL - 3 µg/mL) / 12 µg/mL = 9 / 12 = 0.75. Second, calculate the hepatic clearance (CLh) using the formula CLh = Qh × E. Here, CLh = 90 L/hr × 0.75 = 67.5 L/hr.
  • A): This is the value of the extraction ratio (E), not the clearance.
  • B): This result comes from an incorrect calculation, possibly multiplying clearance by the exiting concentration (90 L/hr * (3/12)).
  • D): This value is the result of multiplying the blood flow by the entering concentration (90 * 1.2), which is dimensionally and conceptually incorrect.

Question 5

A 1000 mg dose of a new antibiotic is administered to a volunteer as a single intravenous bolus. The area under the plasma concentration-time curve from time zero to infinity (AUC₀-∞) is measured to be 50 mg·hr/L. What is the total body clearance (CL) of this drug?

  1. 0.05 L/hr
  2. 500 L/hr
  3. 50,000 L/hr
  4. 20 L/hr (correct answer)
Explanation: When you encounter pharmacokinetics problems involving clearance, remember that clearance represents the body's efficiency at eliminating a drug from the plasma. The fundamental relationship you need is the clearance equation: CL=DoseAUCCL = \frac{Dose}{AUC}, where the dose is the amount administered and AUC is the area under the plasma concentration-time curve. Here, you're given a 1000 mg IV bolus dose and an AUC₀₋∞ of 50 mg·hr/L. Applying the formula: CL=1000 mg50 mg\cdotphr/L=20 L/hrCL = \frac{1000 \text{ mg}}{50 \text{ mg·hr/L}} = 20 \text{ L/hr}. This means the body clears 20 liters of plasma of this antibiotic every hour. Let's examine why the other options are incorrect. Choice A (0.05 L/hr) results from inverting the calculation—dividing AUC by dose instead of dose by AUC. This would represent an impossibly slow clearance. Choice B (500 L/hr) comes from incorrectly multiplying dose by AUC rather than dividing, yielding an unrealistically high clearance that would exceed normal cardiac output. Choice C (50,000 L/hr) represents the same multiplication error but with an even more extreme result. The key study tip: Always remember that clearance equals dose divided by AUC, not the reverse. For IV bolus doses, this relationship is straightforward since 100% of the drug reaches systemic circulation. Practice recognizing the units—clearance should always be in volume per time (L/hr, mL/min), which helps you catch calculation errors.

Question 6

Methamphetamine, a weak base with a pKa of 10.0, is eliminated in part by the kidneys. A patient who uses the drug chronically also consumes large quantities of cranberry juice, which is known to acidify the urine, typically to a pH of 5.0. How does this chronic urinary acidification affect the renal clearance and elimination half-life of methamphetamine?

  1. Increases renal clearance and decreases the half-life. (correct answer)
  2. Decreases renal clearance and increases the half-life.
  3. Increases renal clearance but does not affect the half-life.
  4. Has no significant effect on renal clearance or half-life.
Explanation: When you encounter questions about weak acids or bases and renal elimination, think about the Henderson-Hasselbalch equation and how urine pH affects drug ionization. The key principle is that ionized drugs are trapped in urine and eliminated more readily, while non-ionized drugs can be reabsorbed. Methamphetamine is a weak base with pKa 10.0. In acidic urine (pH 5.0), the drug becomes protonated and ionized. Using the Henderson-Hasselbalch equation: when pH is much lower than pKa (5.0 vs 10.0), the difference is 5 pH units, meaning the ionized form predominates by a factor of 100,000:1. This highly ionized drug cannot cross lipid membranes to be reabsorbed by renal tubules, so it's trapped in urine and eliminated rapidly. Higher renal clearance leads to faster drug removal from the body, decreasing the elimination half-life. Looking at the options: A) correctly identifies that acidic urine increases renal clearance and decreases half-life for this weak base. B) describes the opposite effect, which would occur if methamphetamine were a weak acid in alkaline urine. C) incorrectly suggests clearance changes wouldn't affect half-life - but for drugs with significant renal elimination, increased clearance directly reduces half-life. D) ignores the dramatic pH effect on a weak base with such a high pKa. Remember this pattern: acidic urine enhances elimination of weak bases, while alkaline urine enhances elimination of weak acids. The greater the difference between urine pH and drug pKa, the more pronounced the effect on renal clearance and elimination kinetics.

Question 7

A new antibiotic is 60% bound to plasma proteins. In a patient with a glomerular filtration rate (GFR) of 100 mL/min, the measured renal clearance of the antibiotic is 160 mL/min. Based on these data, what is the most likely mechanism of renal handling for this drug?

  1. Glomerular filtration only
  2. Glomerular filtration with net tubular reabsorption
  3. Glomerular filtration with net tubular secretion (correct answer)
  4. Tubular secretion with complete reabsorption
Explanation: This is a multi-step reasoning question. First, determine the amount of drug cleared by filtration. Only the unbound fraction of a drug is filtered by the glomerulus. The unbound fraction (fu) is 1 - 0.60 = 0.40. The rate of filtration clearance is GFR × fu. So, filtration clearance = 100 mL/min × 0.40 = 40 mL/min. The total measured renal clearance is 160 mL/min. Since the total renal clearance (160 mL/min) is greater than the clearance by filtration alone (40 mL/min), there must be an additional elimination mechanism. This additional mechanism is active tubular secretion.
  • A): Incorrect, as the measured clearance is much higher than the calculated filtration clearance.
  • B): Incorrect. Net reabsorption would result in a total renal clearance that is less than the filtration clearance.
  • D): Incorrect. Complete reabsorption would lead to a clearance near zero.

Question 8

A new therapeutic agent is developed for a chronic condition. To rapidly achieve a therapeutic concentration of 10 mg/L and maintain it, a dosing regimen is designed. The drug's volume of distribution (Vd) is 50 L and its total body clearance (CL) is 5 L/hr. The regimen consists of an initial IV loading dose followed by a continuous IV infusion. The loading dose and maintenance infusion rate should be calculated based on which parameters, respectively?

  1. CL and Vd
  2. Vd and CL (correct answer)
  3. Half-life and Vd
  4. CL and Half-life
Explanation: The loading dose is designed to rapidly fill the volume of distribution to the target concentration. The formula is: Loading Dose = Target Concentration × Vd. In this case, 10 mg/L × 50 L = 500 mg. The maintenance dose (or infusion rate) is designed to replace the amount of drug that is being eliminated from the body, in order to keep the concentration at steady state. The formula is: Maintenance Rate = Target Concentration × CL. In this case, 10 mg/L × 5 L/hr = 50 mg/hr. Therefore, the loading dose is based on Vd, and the maintenance rate is based on CL.
  • A): This reverses the correct relationship.
  • C) & D): Half-life is a dependent variable derived from Vd and CL (t₁/₂ = 0.693 × Vd / CL). While important, Vd and CL are the primary parameters used to calculate the loading and maintenance doses, respectively.

Question 9

An 82-year-old female patient with normal hepatic function is prescribed a new medication. The drug is a small, hydrophilic molecule that is not metabolized and is not significantly bound to plasma proteins. It is eliminated from the body entirely via the kidneys. Which pharmacokinetic parameter is most crucial to consider when selecting an initial dose for this patient compared to a 30-year-old adult?

  1. Hepatic extraction ratio
  2. Volume of distribution
  3. Oral bioavailability
  4. Estimated creatinine clearance (correct answer)
Explanation: When you encounter a pharmacology question about dosing in elderly patients, focus on how aging affects drug clearance and elimination. The key insight here is that this drug has very specific characteristics: it's hydrophilic, not metabolized, not protein-bound, and eliminated entirely by the kidneys. Since this drug is eliminated exclusively through renal excretion and the patient is 82 years old, you must consider that kidney function naturally declines with age. Even with "normal" function for her age, an 82-year-old typically has significantly reduced creatinine clearance compared to a 30-year-old. Lower creatinine clearance means slower drug elimination, leading to drug accumulation and potential toxicity if you use standard adult doses. Therefore, estimated creatinine clearance (D) is the most crucial parameter for initial dosing. Let's examine why the other options don't apply here. Hepatic extraction ratio (A) is irrelevant because the drug isn't metabolized by the liver. Volume of distribution (B) might change slightly with age due to body composition changes, but since the drug is hydrophilic and not protein-bound, these changes would be minimal and less critical than renal clearance. Oral bioavailability (C) isn't the primary concern since the question focuses on choosing an appropriate dose rather than route of administration, and bioavailability doesn't significantly change with normal aging. Remember this pattern: For any drug eliminated primarily by the kidneys in elderly patients, always assess renal function first. Age-related decline in kidney function is predictable and clinically significant, making creatinine clearance your most important dosing consideration.

Question 10

A drug is known to follow zero-order elimination kinetics at concentrations above 20 mg/L. A patient who has overdosed has a plasma concentration of 60 mg/L. After 8 hours, the concentration has fallen to 50 mg/L. Assuming the concentration remains in the zero-order range, how much additional time will be required for the concentration to fall from 40 mg/L to 20 mg/L?

  1. 8 hours
  2. 12 hours
  3. 24 hours
  4. 16 hours (correct answer)
Explanation: When you encounter zero-order elimination kinetics, remember that the drug is eliminated at a constant rate (mg/hour), not a constant fraction per hour like first-order kinetics. This typically occurs when elimination pathways become saturated, as often happens in overdose situations. To find the elimination rate, use the given data: the concentration dropped from 60 mg/L to 50 mg/L in 8 hours. This represents a decrease of 10 mg/L over 8 hours, giving an elimination rate of 10 mg/L8 hours=1.25 mg/L per hour\frac{10 \text{ mg/L}}{8 \text{ hours}} = 1.25 \text{ mg/L per hour} Since zero-order kinetics maintains this constant rate throughout the concentration range, you can calculate any time interval. To go from 40 mg/L to 20 mg/L requires eliminating 20 mg/L. At 1.25 mg/L per hour: 20 mg/L1.25 mg/L per hour=16 hours\frac{20 \text{ mg/L}}{1.25 \text{ mg/L per hour}} = 16 \text{ hours} Answer choice A (8 hours) incorrectly assumes the same time as the initial measurement period. Choice B (12 hours) might result from miscalculating the elimination rate. Choice C (24 hours) could come from incorrectly applying first-order kinetics principles or mathematical errors. The correct answer is D (16 hours). Remember: zero-order elimination means constant rate removal, so always calculate the mg/L per hour first, then divide the concentration change needed by this rate. This pattern appears frequently in toxicology scenarios involving alcohol, phenytoin, and salicylate overdoses.

Question 11

A drug is extensively metabolized in the liver to an inactive glucuronide conjugate, which is then excreted into the bile. A significant portion of this conjugate is hydrolyzed back to the active parent drug by intestinal bacteria and reabsorbed. Which co-administered agent would be most likely to decrease the half-life of the parent drug?

  1. A broad-spectrum oral antibiotic (correct answer)
  2. A proton pump inhibitor, such as omeprazole
  3. An anticholinergic agent that slows gut motility
  4. A CYP3A4 enzyme inducer, such as rifampin
Explanation: The process described is enterohepatic recirculation, which acts as a reservoir for the drug and prolongs its duration of action and half-life. The key step is the hydrolysis of the conjugate back to the parent drug by intestinal bacteria. A broad-spectrum oral antibiotic would eliminate these bacteria, interrupting the recirculation pathway. This would prevent the reabsorption of the drug, increase its net clearance from the body, and thereby decrease its elimination half-life.
  • B): A proton pump inhibitor affects gastric pH but would not interfere with the bacterial hydrolysis in the intestine.
  • C): An agent that slows gut motility would increase the transit time, potentially allowing more time for hydrolysis and reabsorption, which would tend to increase or prolong the half-life.
  • D): While a CYP3A4 inducer might affect metabolism if the drug is a substrate, the question specifically asks about interrupting the described recirculation loop, which is the more direct and certain mechanism.

Question 12

A drug exhibits first-order elimination kinetics at therapeutic doses but switches to zero-order kinetics in overdose situations. A patient on a stable maintenance dose that produces a steady-state concentration of 10 mg/L (within the first-order range) has their dose doubled. After the dose is doubled, the new steady-state concentration is found to be 35 mg/L (within the zero-order range). If the dose were to be tripled from the original maintenance dose, the new steady-state concentration would be expected to:

  1. be approximately 30 mg/L, reflecting a linear dose-concentration relationship.
  2. increase to a value disproportionately greater than 35 mg/L. (correct answer)
  3. remain near 35 mg/L due to saturation of elimination pathways.
  4. be unpredictable without knowing the drug's Michaelis-Menten constant (Km).
Explanation: When a drug's elimination saturates (zero-order kinetics), clearance is no longer constant but decreases as concentration increases. Therefore, a given increase in dose leads to a disproportionately larger increase in steady-state concentration. The patient's dose was doubled, but the concentration more than tripled (10 mg/L to 35 mg/L), confirming saturation. A further increase in dose (tripling the original) will push the saturated system even further, causing the concentration to rise to a level significantly and disproportionately higher than the 35 mg/L seen with doubling the dose.
  • A): Incorrectly assumes a linear (first-order) relationship, which the data in the stem has already disproven.
  • C): Incorrect. Saturation means the rate of elimination is maximal, not that the concentration has reached a maximum. Adding more drug will continue to increase the concentration.
  • D): While knowing Km would allow for precise calculation, the qualitative outcome (a disproportionately large increase) is predictable based on the principles of zero-order kinetics shown in the stem.

Question 13

A patient with severe liver cirrhosis develops hypoalbuminemia. The patient is taking a drug that is 98% bound to plasma albumin, has a low hepatic extraction ratio, and is cleared exclusively by hepatic metabolism. How will the patient's hypoalbuminemia most likely affect the drug's total plasma concentration at steady state (Css) and the concentration of pharmacologically active (unbound) drug?

  1. Total Css will decrease, while the unbound concentration remains relatively stable. (correct answer)
  2. Total Css will increase, and the unbound concentration will also increase.
  3. Total Css will remain stable, while the unbound concentration will decrease.
  4. Total Css and unbound concentration will both decrease significantly.
Explanation: For a low-extraction drug, hepatic clearance is 'capacity-limited' and depends on the intrinsic enzyme activity and the unbound fraction of the drug (CL ≈ fu × CL_int). Hypoalbuminemia increases the unbound fraction (fu). This increase in fu leads to a proportional increase in the drug's clearance. At steady state, Css = Dosing Rate / CL. Because clearance increases, the total steady-state concentration will decrease. However, the unbound (active) concentration at steady state (Css,u) is determined by Dosing Rate / CL_int. Since neither the dosing rate nor the intrinsic clearance (enzyme activity) has changed, the unbound concentration will remain relatively stable. The body effectively clears the excess unbound drug, resulting in a lower total concentration but a similar therapeutic effect.
  • B): Incorrect because the increased clearance will lower the total Css, not increase it.
  • C): Incorrect because the unbound fraction increases, leading to higher clearance and lower total Css.
  • D): Incorrect because the unbound concentration, which drives the therapeutic effect, is expected to remain relatively stable.

Question 14

A drug is extensively metabolized in the liver to an inactive glucuronide conjugate, which is then excreted into the bile. A significant portion of this conjugate is hydrolyzed back to the active parent drug by intestinal bacteria and reabsorbed. Which co-administered agent would be most likely to decrease the half-life of the parent drug?

  1. A broad-spectrum oral antibiotic (correct answer)
  2. A proton pump inhibitor, such as omeprazole
  3. An anticholinergic agent that slows gut motility
  4. A CYP3A4 enzyme inducer, such as rifampin
Explanation: The process described is enterohepatic recirculation, which acts as a reservoir for the drug and prolongs its duration of action and half-life. The key step is the hydrolysis of the conjugate back to the parent drug by intestinal bacteria. A broad-spectrum oral antibiotic would eliminate these bacteria, interrupting the recirculation pathway. This would prevent the reabsorption of the drug, increase its net clearance from the body, and thereby decrease its elimination half-life.
  • B): A proton pump inhibitor affects gastric pH but would not interfere with the bacterial hydrolysis in the intestine.
  • C): An agent that slows gut motility would increase the transit time, potentially allowing more time for hydrolysis and reabsorption, which would tend to increase or prolong the half-life.
  • D): While a CYP3A4 inducer might affect metabolism if the drug is a substrate, the question specifically asks about interrupting the described recirculation loop, which is the more direct and certain mechanism.

Question 15

A patient in the intensive care unit has overdosed on a toxic substance. The clinical team is considering hemodialysis to enhance its elimination. Which of the following properties of the substance would make it least likely to be effectively removed by hemodialysis?

  1. High water solubility
  2. Molecular weight of 300 Daltons
  3. Volume of distribution of 400 L (correct answer)
  4. Plasma protein binding of 10%
Explanation: Hemodialysis removes substances from the blood. For it to be effective, a significant fraction of the drug in the body must be present in the plasma. A very large volume of distribution (Vd), such as 400 L (much larger than total body water), indicates that the drug is extensively distributed into tissues and is not in the plasma. Therefore, dialysis would only be able to clear the small amount of drug circulating in the blood, making it an ineffective method of removal for the total body burden.
  • A): High water solubility is a favorable property for dialysis, as it allows the drug to readily dissolve in the dialysate.
  • B): A low to moderate molecular weight (typically < 500 Daltons) is favorable, allowing the molecule to pass through the pores of the dialysis membrane.
  • D): Low plasma protein binding is favorable, as only the unbound drug can be removed by dialysis.

Question 16

An 82-year-old female patient with normal hepatic function is prescribed a new medication. The drug is a small, hydrophilic molecule that is not metabolized and is not significantly bound to plasma proteins. It is eliminated from the body entirely via the kidneys. Which pharmacokinetic parameter is most crucial to consider when selecting an initial dose for this patient compared to a 30-year-old adult?

  1. Hepatic extraction ratio
  2. Volume of distribution
  3. Oral bioavailability
  4. Estimated creatinine clearance (correct answer)
Explanation: When you encounter a pharmacology question about dosing in elderly patients, focus on how aging affects drug clearance and elimination. The key insight here is that this drug has very specific characteristics: it's hydrophilic, not metabolized, not protein-bound, and eliminated entirely by the kidneys. Since this drug is eliminated exclusively through renal excretion and the patient is 82 years old, you must consider that kidney function naturally declines with age. Even with "normal" function for her age, an 82-year-old typically has significantly reduced creatinine clearance compared to a 30-year-old. Lower creatinine clearance means slower drug elimination, leading to drug accumulation and potential toxicity if you use standard adult doses. Therefore, estimated creatinine clearance (D) is the most crucial parameter for initial dosing. Let's examine why the other options don't apply here. Hepatic extraction ratio (A) is irrelevant because the drug isn't metabolized by the liver. Volume of distribution (B) might change slightly with age due to body composition changes, but since the drug is hydrophilic and not protein-bound, these changes would be minimal and less critical than renal clearance. Oral bioavailability (C) isn't the primary concern since the question focuses on choosing an appropriate dose rather than route of administration, and bioavailability doesn't significantly change with normal aging. Remember this pattern: For any drug eliminated primarily by the kidneys in elderly patients, always assess renal function first. Age-related decline in kidney function is predictable and clinically significant, making creatinine clearance your most important dosing consideration.

Question 17

A new therapeutic agent is developed for a chronic condition. To rapidly achieve a therapeutic concentration of 10 mg/L and maintain it, a dosing regimen is designed. The drug's volume of distribution (Vd) is 50 L and its total body clearance (CL) is 5 L/hr. The regimen consists of an initial IV loading dose followed by a continuous IV infusion. The loading dose and maintenance infusion rate should be calculated based on which parameters, respectively?

  1. CL and Vd
  2. Vd and CL (correct answer)
  3. Half-life and Vd
  4. CL and Half-life
Explanation: The loading dose is designed to rapidly fill the volume of distribution to the target concentration. The formula is: Loading Dose = Target Concentration × Vd. In this case, 10 mg/L × 50 L = 500 mg. The maintenance dose (or infusion rate) is designed to replace the amount of drug that is being eliminated from the body, in order to keep the concentration at steady state. The formula is: Maintenance Rate = Target Concentration × CL. In this case, 10 mg/L × 5 L/hr = 50 mg/hr. Therefore, the loading dose is based on Vd, and the maintenance rate is based on CL.
  • A): This reverses the correct relationship.
  • C) & D): Half-life is a dependent variable derived from Vd and CL (t₁/₂ = 0.693 × Vd / CL). While important, Vd and CL are the primary parameters used to calculate the loading and maintenance doses, respectively.

Question 18

A 1000 mg dose of a new antibiotic is administered to a volunteer as a single intravenous bolus. The area under the plasma concentration-time curve from time zero to infinity (AUC₀-∞) is measured to be 50 mg·hr/L. What is the total body clearance (CL) of this drug?

  1. 0.05 L/hr
  2. 500 L/hr
  3. 50,000 L/hr
  4. 20 L/hr (correct answer)
Explanation: When you encounter pharmacokinetics problems involving clearance, remember that clearance represents the body's efficiency at eliminating a drug from the plasma. The fundamental relationship you need is the clearance equation: CL=DoseAUCCL = \frac{Dose}{AUC}, where the dose is the amount administered and AUC is the area under the plasma concentration-time curve. Here, you're given a 1000 mg IV bolus dose and an AUC₀₋∞ of 50 mg·hr/L. Applying the formula: CL=1000 mg50 mg\cdotphr/L=20 L/hrCL = \frac{1000 \text{ mg}}{50 \text{ mg·hr/L}} = 20 \text{ L/hr}. This means the body clears 20 liters of plasma of this antibiotic every hour. Let's examine why the other options are incorrect. Choice A (0.05 L/hr) results from inverting the calculation—dividing AUC by dose instead of dose by AUC. This would represent an impossibly slow clearance. Choice B (500 L/hr) comes from incorrectly multiplying dose by AUC rather than dividing, yielding an unrealistically high clearance that would exceed normal cardiac output. Choice C (50,000 L/hr) represents the same multiplication error but with an even more extreme result. The key study tip: Always remember that clearance equals dose divided by AUC, not the reverse. For IV bolus doses, this relationship is straightforward since 100% of the drug reaches systemic circulation. Practice recognizing the units—clearance should always be in volume per time (L/hr, mL/min), which helps you catch calculation errors.

Question 19

A patient stabilized on warfarin (a low-extraction drug with a narrow therapeutic index, metabolized by CYP2C9) is started on fluconazole, a potent inhibitor of CYP2C9. Which of the following pharmacokinetic changes is the primary driver of the clinically significant interaction?

  1. A decrease in the hepatic extraction ratio of warfarin
  2. A reduction in the intrinsic clearance of warfarin (correct answer)
  3. An increase in hepatic blood flow
  4. Displacement of warfarin from albumin binding sites
Explanation: Warfarin is a low-extraction drug, meaning its clearance is capacity-limited and described by the equation CL ≈ fu × CL_int. Fluconazole inhibits CYP2C9, the enzyme responsible for warfarin's metabolism. This directly reduces the intrinsic clearance (CL_int), which is a measure of the metabolic capacity of the liver. This reduction in CL_int is the primary mechanism that leads to decreased overall clearance, increased half-life, and accumulation of warfarin to potentially toxic levels.
  • A): While a decrease in intrinsic clearance will lead to a decrease in the extraction ratio, the fundamental cause is the change in CL_int, not the other way around.
  • C): Hepatic blood flow does not significantly influence the clearance of low-extraction drugs.
  • D): While some drugs can displace warfarin from albumin, increasing the unbound fraction (fu), this effect is often transient and less significant than the profound and sustained effect of metabolic inhibition on intrinsic clearance.

Question 20

A patient presents with an overdose of a weakly basic drug with a pKa of 8.0. The drug is eliminated primarily by the kidneys. Assuming the patient's glomerular filtration is normal, which intervention would most effectively increase the rate of elimination of this drug?

  1. Intravenous administration of sodium bicarbonate to achieve a urine pH of 8.0
  2. Intravenous administration of ammonium chloride to achieve a urine pH of 6.0 (correct answer)
  3. Initiation of a high-flow intravenous saline drip to induce diuresis
  4. Oral administration of activated charcoal every 4 hours
Explanation: To enhance the renal elimination of a drug via 'ion trapping,' the goal is to ionize the drug within the renal tubules to prevent its passive reabsorption. For a weak base, this is achieved by acidifying the urine. According to the Henderson-Hasselbalch equation, when the urine pH (6.0) is lower than the drug's pKa (8.0), the drug will be predominantly in its ionized, water-soluble form, which is trapped in the filtrate and excreted. Ammonium chloride is a urinary acidifier.
  • A): Administering sodium bicarbonate would alkalinize the urine. This would increase the proportion of the weakly basic drug in its non-ionized, lipid-soluble form, thereby increasing its passive reabsorption and decreasing its renal elimination.
  • C): While forced diuresis can increase drug elimination, it is generally less effective than pH manipulation and can cause electrolyte imbalances. The primary mechanism for enhancement in this case is ion trapping.
  • D): Activated charcoal is used to bind drugs in the gastrointestinal tract to prevent their initial absorption. It is not effective for a drug that has already been absorbed and is being eliminated by the kidneys.